Search
Life Sciences
• New investors Fidelity Management & Research Company, Janus Henderson Investors and Blackstone Multi-Asset Investing join Series C syndicate led by Venrock Healthcare...
Axial Therapeutics today announced that it has rebranded as Vertero Therapeutics, a biotechnology company breaking barriers in neurodegenerative disease treatment. The new...
Enterome, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, announces today that the U.S. Food and Drug Administration (FDA) has...
Sunrise Group, known as a leader in sleep health technology, has announced a funding round of $29 million dedicated to expanding Dreem Health, its innovative digital sleep...
Kapsera, a pioneer in sustainable microencapsulation for the agri-food industry, announces the entry of Seventure Partners into its capital as part of its Series A financing...
Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), today...
60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2).
EO2463 plus R2 was well tolerated in patients with...
The Company, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with...
Enterome, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing.
Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, will present positive data from its Phase 1/2 clinical study with...
